0.4697

3.96% 0.0179

Century Therapeutics Inc (IPSC)

Overview News Price History Option Chain Financials Discussions Forecast

Century Therapeutics Inc stock is traded at $0.4697, with a volume of 462.50K. It is up +3.96% in the last 24 hours and down -31.21% over the past month.

Previous Close:

$0.4518

Open:

$0.453

24h Volume:

462.50K

Relative Volume:

0.98

Market Cap:

$38.88M

Revenue:

$2.24M

Net Income/Loss:

$-136.67M

P/E Ratio:

-0.2051

EPS:

-2.29

Net Cash Flow:

$-102.08M

1W Performance:

-15.52%

1M Performance:

-31.21%

6M Performance:

-70.83%

1Y Performance:

-87.61%

1-Day Range:

$0.453

$0.4739

1-Week Range:

$0.4512

$0.5846

52-Week Range:

$0.4512

$4.4278

Century Therapeutics Inc Stock (IPSC) Company Profile

Name

Century Therapeutics Inc

Sector

Healthcare (1161)

Industry

Biotechnology (676)

Phone

215-981-4000

Address

25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA

Employee

Twitter

Next Earnings Date

2025-03-19

Latest SEC Filings

IPSC's Discussions on Twitter

Compare IPSC with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IPSC Century Therapeutics Inc	0.4697	38.88M	2.24M	-136.67M	-102.08M	-2.29
VRTX Vertex Pharmaceuticals Inc	483.49	124.48B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	625.60	67.45B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	583.62	35.60B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	266.83	34.53B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	274.78	29.15B	3.81B	-644.79M	-669.77M	-6.24

Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-08-24	Initiated	Rodman & Renshaw	Buy
Aug-28-23	Downgrade	JP Morgan	Overweight → Neutral
Dec-27-22	Initiated	Chardan Capital Markets	Buy
Oct-31-22	Initiated	Guggenheim	Buy
Oct-10-22	Initiated	Canaccord Genuity	Buy
May-23-22	Initiated	H.C. Wainwright	Buy
May-12-22	Initiated	William Blair	Mkt Perform
Jul-13-21	Initiated	BofA Securities	Buy
Jul-13-21	Initiated	JP Morgan	Overweight
Jul-13-21	Initiated	Piper Sandler	Overweight

View All

Century Therapeutics Inc Stock (IPSC) Latest News

Mar 30, 2025

Guggenheim Reiterates Buy Rating for Century Therapeutics (NASDAQ:IPSC) - Defense World

Mar 30, 2025

Mar 28, 2025

What is Chardan Capital’s Estimate for IPSC FY2025 Earnings? - Defense World

Mar 28, 2025

Mar 25, 2025

Century Therapeutics (IPSC) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

Mar 25, 2025

Century Therapeutics (NASDAQ:IPSC) Price Target Lowered to $7.00 at Chardan Capital - Defense World

Mar 25, 2025

William Blair Issues Optimistic Forecast for IPSC Earnings - The AM Reporter

Mar 25, 2025

Mar 24, 2025

Carnival To Rally Around 48%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga

Mar 24, 2025

Q1 EPS Estimate for Century Therapeutics Boosted by Analyst - Defense World

Mar 24, 2025

Chardan Cuts Price Target on Century Therapeutics to $7 From $11, Keeps Buy Rating - MarketScreener

Mar 24, 2025

Mar 23, 2025

Century Therapeutics Announces Strategic Pipeline Shift and 2024 Financial Results - MSN

Mar 23, 2025

Guggenheim Lowers Century Therapeutics (NASDAQ:IPSC) Price Target to $5.00 - Defense World

Mar 23, 2025

Piper Sandler Cuts Century Therapeutics (NASDAQ:IPSC) Price Target to $2.00 - Defense World

Mar 23, 2025

Mar 22, 2025

Guggenheim cuts Century Therapeutics target to $5, keeps Buy rating By Investing.com - Investing.com Canada

Mar 22, 2025

What is William Blair’s Estimate for IPSC Q3 Earnings? - Defense World

Mar 22, 2025

Mar 21, 2025

Demystifying Century Therapeutics: Insights From 4 Analyst Reviews - Benzinga

Mar 21, 2025

Mar 20, 2025

Century Therapeutics Reports 2024 Financial Results and Strategic Updates - TipRanks

Mar 20, 2025

Leerink Partners Adjusts Price Target on Century Therapeutics to $8 From $13, Keeps Outperform Rating - Marketscreener.com

Mar 20, 2025

Mar 19, 2025